On Monday, Insulet reached a key technical benchmark, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an improvement to 93, a rise from 86 the day before.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating of at least 80 at the beginning of a new run.
Looking For The Best Stocks To Buy And Watch? Start Here
Insulet is now considered extended and out of buy range after clearing a 243.98 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
While EPS growth decreased in the company's most recently reported quarter from 45% to 27%, sales rose 26%, up from 23% in the prior report.
The company earns the No. 1 rank among its peers in the Medical-Products industry group. Insulet and Pro-Dex are also among the group's highest-rated stocks.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
